Search bioRxiv⌕ Search

Biology subjects

Laudette, M.

Publications and source records attributed to Laudette, M..

2 recordsLinked to original sources

A Heart Disease-Associated TSPO Variant Alters Transmembrane Helix Dynamics

The 18-kDa translocator protein TSPO is an outer mitochondrial membrane protein involved in cholesterol transport, stress response, and cellular metabolism. Although its five-helix architecture is conserved across species, the structural and dynamic features of human TSPO remain unresolved. Using solution NMR spectroscopy, we characterize the conformational dynamics of human TSPO in complex with a third-generation diagnostic ligand. We identify a dynamic N-terminal segment of the first transmembrane helix that does not form a stably populated helix but instead defines a flexible boundary between the cytosolic region and the transmembrane core. The common disease-associated A14V variant reduces this conformational heterogeneity by introducing short-range contacts and redistributing backbone dynamics across the protein. These changes preserve the overall fold while locally stabilizing the N-terminal transmembrane helix toward the VDAC interaction interface. Our findings reveal a human-specific dynamic architecture of TSPO and link variant-induced stabilization to modulation of transmembrane helix dynamics.

biophysics↗

EPAC1 Inhibition Protects the Heart from Doxorubicin-Induced Toxicity

Anthracyclines, such as doxorubicin (Dox), are widely used chemotherapeutic agents for the treatment of solid tumors and hematologic malignancies. However, they frequently induce cardiotoxicity leading to dilated cardiomyopathy and heart failure. This study sought to investigate the role of the Exchange Protein directly Activated by cAMP (EPAC) in Dox-induced cardiotoxicity and the potential cardioprotective effects of EPAC inhibition. We show that Dox induces DNA damage and cardiomyocyte cell death with apoptotic features. Dox also led to an increase in both cAMP concentration and EPAC1 activity. The pharmacological inhibition of EPAC1 (with CE3F4) but not EPAC2 alleviated the whole Dox-induced pattern of alterations. When administered in vivo, Dox-treated WT mice developed a dilated cardiomyopathy which was totally prevented in EPAC1 KO mice. Moreover, EPAC1 inhibition potentiated Dox-induced cell death in several human cancer cell lines. Thus, EPAC1 inhibition appears as a potential therapeutic strategy to limit Dox-induced cardiomyopathy without interfering with its antitumoral activity.

pathology↗